Can peptides be taken orally? Pills vs shots
Semaglutide pills are approved. BPC-157 pills, sprays and creams are not proven.
By the Peptide Science Desk Editorial TeamFact-checked against FDA and official sources · Not yet reviewed by a licensed clinician. How we check facts

Can peptides be taken orally?
- A few can. Peptides are small proteins. Like protein in food, most get broken down in the gut before they reach the blood.
- Semaglutide pills work because they contain SNAC, an ingredient that helps the drug get absorbed in the stomach, say their FDA labels.
- Other FDA-approved peptide pills exist for rare uses: octreotide capsules (Mycapssa) for acromegaly, and desmopressin tablets (DDAVP) for a type of diabetes insipidus.
- Linzess (linaclotide) is a peptide pill for constipation. Its label says it is barely absorbed. It works inside the gut.
Do oral peptides work as well as injections?
- For semaglutide, the pill and the shot both work in big trials. But the trials were separate, so they cannot be compared fairly.
- Shot: in STEP 1, people lost about 14.9% of their weight in 68 weeks, vs 2.4% on placebo.
- Pill: in OASIS 4, people on the daily semaglutide pill lost about 13.6% in 64 weeks, vs 2.2% on placebo.
- The Wegovy pill is taken every day. The Wegovy shot is taken once a week.
- The pill has strict rules on its label: take it on an empty stomach in the morning with a little plain water, and wait at least 30 minutes before eating, drinking or other pills.
Is there a Zepbound or tirzepatide pill?
- No. Every tirzepatide label we found in the FDA drug label database is a shot (checked October 22, 2026).
- Lilly’s weight-loss pill is Foundayo (orforglipron). It works on the GLP-1 switch, but it is not a peptide. It is a small chemical.
- In its big trial (ATTAIN-1), people on the top dose lost about 11.2% of their weight in 72 weeks, vs 2.1% on placebo.
Do BPC-157 capsules or oral BPC-157 work?
- Nobody knows. BPC-157 is not FDA approved in any form.
- A 2026 review found only 3 small studies of BPC-157 in people (30 people in total). None of them tested pills or capsules.
- Claims about oral BPC-157 come from animal and lab studies. Those do not prove it works in people.
- No data on pills also means no data on their safety. Unknown is not the same as safe.
Do peptide nasal sprays work?
- One kind is FDA approved: desmopressin nasal spray, for central diabetes insipidus.
- Selank and Semax nasal sprays are not FDA approved. The FDA says there is little or no safety data for Semax.
- Bremelanotide (PT-141) was tested as a nasal spray in one label study, but the approved Vyleesi is a shot.
- A spray that is not approved has no FDA check of what is inside or how much.
Do peptide creams or GLP-1 patches work?
- Skin creams with peptides are usually sold as cosmetics. The FDA says cosmetics do not need FDA approval before sale.
- The FDA says a product that claims to regrow hair or "regenerate cells" is a drug under the law, even if it is sold as a cosmetic.
- GLP-1 patches: every semaglutide and tirzepatide label we found in the FDA database is a shot or a pill. We found no approved patch.
- On March 31, 2026, the FDA sent a warning letter to an online seller of a "GLP-1" microneedle patch. It said the patch was an unapproved new drug.
Are peptide pills safer than shots?
- Not clearly. The Wegovy pill and shot share the same label warnings.
- Pills still cause stomach side effects. In OASIS 1, 80% of people on a semaglutide pill had stomach side effects, vs 46% on placebo. They were mostly mild to medium.
- Shots can cause skin reactions where you inject. Labels say never share a pen, even with a new needle.
- The semaglutide pill labels say breastfeeding is not recommended, because SNAC could build up in babies.
- How well it works, how safe it is, and FDA status are separate questions.
The numbers in charts
Weight loss: GLP-1 pills vs the shot
% of starting body weight lost, drug vs placebo (fake medicine)
Semaglutide shot 2.4 mg (Wegovy)STEP 1 · 1,961 adults · 68 weeks
Semaglutide pill 25 mg (Wegovy tablets)OASIS 4 · 307 adults · 64 weeks
Semaglutide pill 50 mgOASIS 1 · 667 adults · 68 weeks · this dose is not sold
Orforglipron pill 36 mg (Foundayo)Not a peptideATTAIN-1 · 3,127 adults · 72 weeks
Different trials, different people: not a head-to-head comparison.
Show the numbers as a table
| Trial | Drug | Placebo |
|---|---|---|
| Semaglutide shot 2.4 mg (Wegovy) STEP 1 · 1,961 adults · 68 weeks | −14.9% | −2.4% |
| Semaglutide pill 25 mg (Wegovy tablets) OASIS 4 · 307 adults · 64 weeks | −13.6% | −2.2% |
| Semaglutide pill 50 mg OASIS 1 · 667 adults · 68 weeks · this dose is not sold | −15.1% | −2.4% |
| Orforglipron pill 36 mg (Foundayo) (Not a peptide) ATTAIN-1 · 3,127 adults · 72 weeks | −11.2% | −2.1% |
How much of the dose reaches your blood
Share of semaglutide that gets into the blood (bioavailability), shot vs pill
Semaglutide shot (Wegovy)Under the skin
Wegovy tabletsSwallowed pill
Rybelsus tabletsSwallowed pill (diabetes)
Most of a peptide pill is broken down in the gut. That is why the pill dose is much bigger than the shot dose.
Show the numbers as a table
| Form | Reaches the blood |
|---|---|
| Semaglutide shot (Wegovy) Under the skin | 89% |
| Wegovy tablets Swallowed pill | about 1–2% |
| Rybelsus tablets Swallowed pill (diabetes) | about 0.4–1% |
Stomach side effects on semaglutide pills
% of adults with any stomach or gut side effect (like nausea or diarrhea)
OASIS 1 (50 mg pill)667 adults · 68 weeks
OASIS 4 (25 mg pill, Wegovy tablets)307 adults · 64 weeks
Many people on placebo also had stomach problems. Most were mild to moderate.
Show the numbers as a table
| Trial | Semaglutide pill | Placebo |
|---|---|---|
| OASIS 1 (50 mg pill) 667 adults · 68 weeks | 80% | 46% |
| OASIS 4 (25 mg pill, Wegovy tablets) 307 adults · 64 weeks | 74.0% | 42.2% |
Studies in people
| Study type | People | Main finding | Limits |
|---|---|---|---|
| Randomized trial: weekly semaglutide shot vs placebo (STEP 1), 2021 | 1,961 adults with obesity or overweight | Weight went down 14.9% vs 2.4% in 68 weeks | Different people and length than the pill trials |
| Randomized trial: daily semaglutide pill vs placebo (OASIS 4), 2025 | 307 adults with obesity or overweight | Weight went down 13.6% vs 2.2% in 64 weeks | Small trial; 4 countries |
| Randomized trial: higher-strength semaglutide pill vs placebo (OASIS 1), 2023 | 667 adults with obesity or overweight | Weight went down 15.1% vs 2.4% in 68 weeks; stomach side effects in 80% vs 46% | This strength is not the approved one |
| Randomized trial: orforglipron pill (Foundayo) vs placebo (ATTAIN-1), 2025 | 3,127 adults with obesity | Weight went down 11.2% (top dose) vs 2.1% in 72 weeks | Not a peptide |
| Review of all human studies: BPC-157, 2026 | 3 small studies, 30 people in total | No study tested pills or capsules | Poor-quality studies |
Pills, shots and sprays at a glance
| Wegovy / Ozempic shot (semaglutide) | Wegovy tablets / Rybelsus (semaglutide pill) | Foundayo pill (orforglipron) | BPC-157 pills or sprays | |
|---|---|---|---|---|
| Is it a peptide? | Yes | Yes | No (small chemical) | Yes |
| FDA status | Approved | Approved | Approved for weight | Not approved |
| How much gets into the blood (label) | 89% | About 1% to 2% (Wegovy and Ozempic tablets) | Not listed this way | Unknown |
| Proof it works in people | Strong | Strong | Strong | None for pills or sprays |
| Safety data | Well studied | Well studied | Studied (newer drug) | Very little |
FAQ
Is the Wegovy pill the same medicine as the Wegovy shot?
It is the same active drug, semaglutide, in a different form. The label says not to use it with other semaglutide products or other GLP-1 drugs.
Why can I not crush or split the semaglutide pill?
The Wegovy label says to swallow the tablets whole and not split, crush, chew or dissolve them. Ask your pharmacist why this matters for your pill.
Can I swallow a peptide that was made for injection?
Do not do this. There are no studies showing it works or is safe, and products sold "for research" are not checked by the FDA.
Are under-the-tongue peptides proven?
We found no FDA-approved under-the-tongue form of semaglutide, tirzepatide or BPC-157. Ask your doctor before trying one.
Does insurance cover the pill or the shot?
It depends on your plan. Ask your plan or pharmacist. We do not list prices.
Is a nasal spray faster than a shot?
It depends on the drug. For the peptides sold online as sprays, no good human studies tell us.
Related pages
- GLP-1: what it is, drugs list and side effectsGLP-1 guide
- GLP-1: Wegovy / Ozempic (semaglutide)FDA approved · Proof: Strong
- GLP-1: Zepbound / Mounjaro (tirzepatide)FDA approved · Proof: Strong
- GLP-1 pill: Foundayo (orforglipron)FDA approved · Proof: Strong
- BPC-157Not approved · Proof: Early
- SemaxNot approved · Proof: Early
- SelankNot approved · Proof: Early
- GHK-CuNot approved · Proof: Early
- Vyleesi (bremelanotide, PT-141)FDA approved · Proof: Some
- Peptides for gut health: what really works?Guide
- Is Zepbound a GLP-1? What GLP-1 really meansGuide
- Liraglutide supplements: is there an over-the-counter version?Guide
- Peptides vs GLP-1: what's the difference?Guide
- Semaglutide vs Tirzepatide: What's the Difference?Guide
- Do peptides really work? The honest answerGuide
- Peptide side effects: what is common and what is serious?Guide
- Peptide side effects checkerTool
- Peptide comparison toolTool
- GLP-1 pill vs shotTool
- GLP-1 price trackerTool
- GLP-1 quiz: which GLP-1 is right for me?Tool
- Compare GLP-1: Wegovy / Ozempic vs GLP-1: Zepbound / MounjaroComparison tool
We never share doses or tell you where to buy. Always ask your doctor. Print our doctor questions sheet.
Sources
- DailyMed (FDA label): Wegovy (semaglutide) injection and tablets prescribing information, revised 6/2026
- DailyMed (FDA label): Rybelsus / Ozempic tablets (semaglutide) prescribing information
- DailyMed (FDA label): Zepbound (tirzepatide) prescribing information
- DailyMed (FDA label): Mounjaro (tirzepatide) prescribing information
- DailyMed (FDA label): Foundayo (orforglipron) tablets prescribing information
- DailyMed (FDA label): Mycapssa (octreotide) capsules prescribing information
- DailyMed (FDA label): DDAVP (desmopressin) tablets prescribing information
- DailyMed (FDA label): Linzess (linaclotide) prescribing information
- DailyMed (FDA label): Desmopressin acetate nasal spray prescribing information
- DailyMed (FDA label): Vyleesi (bremelanotide) prescribing information
- PubMed: Wilding et al., Once-weekly semaglutide in adults with overweight or obesity (STEP 1), NEJM 2021
- PubMed: Wharton et al., Oral semaglutide in adults with overweight or obesity (OASIS 4), NEJM 2025
- PubMed: Knop et al., Oral semaglutide once a day in adults with overweight or obesity (OASIS 1), Lancet 2023
- PubMed: Wharton et al., Orforglipron, an oral small-molecule (nonpeptide) GLP-1 drug for obesity (ATTAIN-1), NEJM 2025
- PubMed: Poolton et al., Human evidence for BPC-157: a systematic review, Acta Orthop Belg 2026
- FDA: Is it a cosmetic, a drug, or both?
- FDA warning letter: FormPour ("GLP-1" microneedle patch is an unapproved new drug), Mar 31, 2026
- FDA: Concerns with unapproved GLP-1 drugs used for weight loss